Mdxhealth S.A. ((MDXH)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest earnings call from Mdxhealth S.A. conveyed a mixed sentiment, reflecting a company in transition. While the call highlighted robust revenue and volume growth, improved gross margins, and a successful acquisition of ExoDx, these positives were counterbalanced by the discontinuation of the germline offering and ongoing net and operating losses. Overall, the sentiment suggests that Mdxhealth is making strategic adjustments for future growth while managing current financial challenges.
Strong Revenue Growth
Mdxhealth reported a significant increase in revenue for the third quarter, reaching $27.4 million. This represents an 18% increase over the previous year, showcasing the company’s ability to grow despite the strategic decision to forego the germline offering.
Positive Adjusted EBITDA
The company achieved positive adjusted EBITDA for the second consecutive quarter, reporting $1 million in Q3. This follows the first profitable quarter in Q2, indicating a positive trend in the company’s financial performance.
Significant Volume Growth
The earnings call highlighted a remarkable 37% growth in total billable volume compared to the prior year. Liquid-based tests saw a 65% increase, while tissue-based tests grew by 18%, underscoring the company’s expanding market presence.
Gross Margin Improvement
Mdxhealth’s gross margins improved to 65.2% from 61.2% in Q3 2024. This improvement was driven by a favorable test mix and operational efficiencies, contributing to the company’s overall financial health.
Successful ExoDx Acquisition
The successful acquisition of ExoDx was a key highlight, expanding Mdxhealth’s sales organization and enhancing cross-selling opportunities. This strategic move is expected to bolster the company’s market position.
Discontinued Germline Offering
In a strategic pivot, Mdxhealth decided to discontinue its entry into the germline market. This decision, although expected to impact 2025 revenue, allows the company to focus on integrating the ExoDx acquisition.
Operating Loss
Despite the improvements, Mdxhealth reported an operating loss of $2.6 million. However, this was a 57% reduction compared to the previous year, indicating progress in managing operational costs.
Net Loss
The net loss for the quarter was $8 million, down from $11.2 million in the prior year. While still a notable negative figure, the reduction reflects the company’s efforts to improve its financial standing.
Forward-Looking Guidance
Looking ahead, Mdxhealth is focusing on strategic growth and operational performance. The company reported an 18% increase in revenue, driven by a 37% increase in billable volume. The integration of the ExoDx acquisition is a priority, with plans to expand the sales force to optimize cross-selling opportunities. Despite setting aside the germline offering, the company remains focused on leveraging the ExoDx acquisition to achieve its revenue guidance of $108-$110 million for 2025.
In summary, Mdxhealth’s earnings call reflects a company navigating through strategic changes and financial challenges. While the company has made significant strides in revenue growth, volume expansion, and operational efficiencies, it continues to face hurdles with net and operating losses. The successful acquisition of ExoDx and the decision to focus on core strengths signal a forward-looking approach aimed at sustainable growth.